Search

Your search keyword '"Wilding, John P.H."' showing total 12 results
Start Over Author "Wilding, John P.H." Publisher wiley
12 results on '"Wilding, John P.H."'

1. New insights into the treatment of obesity

Author

Blüher, Matthias, primary, Aras, Mohini, additional, Aronne, Louis J., additional, Batterham, Rachel L., additional, Giorgino, Francesco, additional, Ji, Linong, additional, Pietiläinen, Kirsi H., additional, Schnell, Oliver, additional, Tonchevska, Elena, additional, and Wilding, John P.H., additional

Published
2023
Full Text
View/download PDF

2. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The <scp>STEP</scp> 1 trial extension

Author

Wilding, John P.H., Batterham, Rachel L., Davies, Melanie, Van Gaal, Luc, Kandler, Kristian, Konakli, Katerina, Lingvay, Ildiko, McGowan, Barbara M., Oral, Tugce Kalayci, Rosenstock, Julio, Wadden, Thomas A., Wharton, Sean, Yokote, Koutaro, Kushner, Robert F., and STEP 1 Study Group

Subjects
Adult, Endocrinology, Cardiovascular Diseases, Endocrinology, Diabetes and Metabolism, Diabetes Mellitus, Glucagon-Like Peptides, Internal Medicine, Humans, Human medicine, Weight Gain
Abstract

Aim To explore changes in body weight and cardiometabolic risk factors after treatment withdrawal in the STEP 1 trial extension. Materials and Methods STEP 1 (NCT03548935) randomized 1961 adults with a body mass index >= 30 kg/m(2) (or >= 27 kg/m(2) with >= 1 weight-related co-morbidity) without diabetes to 68 weeks of once-weekly subcutaneous semaglutide 2.4 mg (including 16 weeks of dose escalation) or placebo, as an adjunct to lifestyle intervention. At week 68, treatments (including lifestyle intervention) were discontinued. An off-treatment extension assessed for a further year a representative subset of participants who had completed 68 weeks of treatment. This subset comprised all eligible participants from any site in Canada, Germany and the UK, and sites in the United States and Japan with the highest main phase recruitment. All analyses in the extension were exploratory. Results Extension analyses included 327 participants. From week 0 to week 68, mean weight loss was 17.3% (SD: 9.3%) with semaglutide and 2.0% (SD: 6.1%) with placebo. Following treatment withdrawal, semaglutide and placebo participants regained 11.6 (SD: 7.7) and 1.9 (SD: 4.8) percentage points of lost weight, respectively, by week 120, resulting in net losses of 5.6% (SD: 8.9%) and 0.1% (SD: 5.8%), respectively, from week 0 to week 120. Cardiometabolic improvements seen from week 0 to week 68 with semaglutide reverted towards baseline at week 120 for most variables. Conclusions One year after withdrawal of once-weekly subcutaneous semaglutide 2.4 mg and lifestyle intervention, participants regained two-thirds of their prior weight loss, with similar changes in cardiometabolic variables. Findings confirm the chronicity of obesity and suggest ongoing treatment is required to maintain improvements in weight and health.

Published
2022

5. The cost‐effectiveness of dapagliflozin in treating high‐risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE‐TIMI 58 trial

Author

McEwan, Phil, primary, Morgan, Angharad R., additional, Boyce, Rebecca, additional, Bergenheim, Klas, additional, Gause‐Nilsson, Ingrid A.M., additional, Bhatt, Deepak L., additional, Leiter, Lawrence A., additional, Johansson, Peter A., additional, Mosenzon, Ofri, additional, Cahn, Avivit, additional, and Wilding, John P.H., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results